ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year ORGO was profitable.
In the past year ORGO has reported a negative cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
Each year in the past 5 years ORGO had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -2.63%, ORGO belongs to the top of the industry, outperforming 87.40% of the companies in the same industry.
Looking at the Return On Equity, with a value of -3.47%, ORGO belongs to the top of the industry, outperforming 89.12% of the companies in the same industry.
ORGO's Return On Invested Capital of 0.16% is amongst the best of the industry. ORGO outperforms 88.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ORGO is significantly below the industry average of 18.09%.

		Industry Rank	Sector Rank
ROA	-2.63%
ROE	-3.47%
ROIC	0.16%

ROA(3y)1.45%

ROA(5y)6.32%

ROE(3y)2.46%

ROE(5y)11.67%

ROIC(3y)3.79%

ROIC(5y)7.32%

1.3 Margins

ORGO's Operating Margin of 0.18% is amongst the best of the industry. ORGO outperforms 88.74% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
ORGO has a Gross Margin of 74.49%. This is amongst the best in the industry. ORGO outperforms 83.40% of its industry peers.
ORGO's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	0.18%
PM (TTM)	N/A
GM	74.49%

OM growth 3Y-34.07%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.17%

GM growth 5Y1.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ORGO is destroying value.
Compared to 1 year ago, ORGO has less shares outstanding
Compared to 5 years ago, ORGO has more shares outstanding
The debt/assets ratio for ORGO has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 3.74 indicates that ORGO is not in any danger for bankruptcy at the moment.
ORGO's Altman-Z score of 3.74 is fine compared to the rest of the industry. ORGO outperforms 70.80% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ORGO is not too dependend on debt financing.
ORGO has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ORGO outperforms 46.95% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	3.74

ROIC/WACC0.02

WACC9.07%

2.3 Liquidity

A Current Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
ORGO's Current ratio of 3.32 is on the low side compared to the rest of the industry. ORGO is outperformed by 60.11% of its industry peers.
ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO's Quick ratio of 2.88 is on the low side compared to the rest of the industry. ORGO is outperformed by 63.55% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.32
Quick Ratio	2.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ORGO have decreased strongly by -90.91% in the last year.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
The Revenue has been growing slightly by 2.24% in the past year.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.

EPS 1Y (TTM)-90.91%

EPS 3Y-37.9%

EPS 5YN/A

EPS Q2Q%66.67%

Revenue 1Y (TTM)2.24%

Revenue growth 3Y0.98%

Revenue growth 5Y13.05%

Sales Q2Q%30.98%

3.2 Future

The Earnings Per Share is expected to grow by 29.27% on average over the next years. This is a very strong growth
ORGO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.70% yearly.

EPS Next Y-58%

EPS Next 2Y-6.73%

EPS Next 3Y29.27%

EPS Next 5YN/A

Revenue Next Year9.76%

Revenue Next 2Y8.03%

Revenue Next 3Y8.7%

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 423.00, ORGO can be considered very expensive at the moment.
88.93% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of ORGO to the average of the S&P500 Index (28.41), we can say ORGO is valued expensively.
With a Price/Forward Earnings ratio of 28.60, ORGO can be considered very expensive at the moment.
ORGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 92.18% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 25.64, ORGO is valued at the same level.

		Industry Rank	Sector Rank
PE	423
Fwd PE	28.6

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaply inside the industry as 93.89% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	23.49

4.3 Compensation for Growth

The decent profitability rating of ORGO may justify a higher PE ratio.
ORGO's earnings are expected to grow with 29.27% in the coming years. This may justify a more expensive valuation.